Dealmaking in 2023
Our panel of veteran industry dealmakers will take a look at the top trends as we enter a new year at the bargaining table.
An in-depth discussion featuring Endpoints EIC John Carroll and ARCH’s Robert Nelson.
AI in biopharma 2023 — there's no looking back
From discovery through trials, we're beyond the early stages of AI in biotech R&D. When the mission is to get to patients faster, drug developers are increasingly looking at technology for the answers. Beyond the initial hype, where is AI poised to make meaningful contributions to R&D? Endpoints publisher Arsalan Arif is convening a panel of leading experts to discuss the state of AI in biotech and the outlook for 2023. How are we getting higher quality targets into clinical trials? How is AI playing a role in clinical trial design? What's the impact of protein structure predicting in drug discovery? What's the outlook for AI in 2023?
This is how we cure cancer
One of the key trends in oncology R&D right now is moving new cancer therapies into the adjuvant arena, combining with better diagnostics and earlier diagnosis to hit cancer at a point it can still be forced into remission. In this roundtable discussion we’ll look at some of the latest advances in combinations and early detection that will give patients the best shot at a curative therapeutic program. Moderated by John Carroll.
The Year Ahead in Washington
A split Congress means little if any legislation is likely to advance this year. What are the must-do pieces of legislation that might be vehicles for action? What should the biopharma industry expect from a Republican House's oversight efforts? And with the 2024 presidential campaigns already gearing up, how will the noise from electoral politics affect markets corporate planning?
One-on-one chat featuring a member of the Endpoints editorial team and an industry leader.
A look at the environment for fundraising. How are venture capitalists and other private investors thinking about deploying and raising capital? What's the appetite for exits? In a down market with financial pressure on company balance sheets, what types of financings should we expect to see?
monday & tuesday - 12:00pm - 6:00pm PST
Network with Endpoints Insiders in our premium space just blocks away from Union Square. Perks include unlimited coffee, WiFi, charging station, lounge-style seating with coworking tables and a chance to mingle with members of the Endpoints team. Endpoints Insider subscription or full-day pass is required to attend.